Johnson & Johnson 1Q Sales Rise on U.S. Growth, Narrows Adjusted EPS Outlook
By Sabela Ojea
Johnson & Johnson said sales rose in the latest quarter, mainly boosted by the U.S. market, and narrowed its full-year adjusted earnings per share outlook.
The healthcare giant on Tuesday posted a net profit of $5.35 billion, or $2.20 a share, compared with a loss of $491 million, or 19 cents a share, for the same period a year earlier.
Stripping out one-time items, the company's earnings per share came in at $2.71, coming ahead of analysts expectations of $2.64, according to FactSet.
Sales rose 2.3% to $21.38 billion, boosted by growth across all geographies expect Asia-Pacific and Africa. Analysts polled by FactSet had forecast slightly higher sales of $21.39 billion.
The company said its topline performance in the U.S. rose 7.8% to $11.62 billion.
"Johnson & Johnson's solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline," Chief Executive Joaquin Duato said.
Regarding its outlook, Johnson & Johnson said it now expects full-year sales of $88 billion to $88.4 billion versus a prior range of $87.8 billion to $88.6 billion, and narrowed its full-year adjusted earnings per share views to $10.57 to $10.72 from $10.55 to $10.75 expected previously.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
Corrections & Amplifications
This article was corrected at 12:02 p.m. ET because it incorrectly said the company cut its full-year adjusted earnings per share outlook. Johnson & Johnson narrowed its full-year adjusted earnings per share outlook.
(END) Dow Jones Newswires
April 16, 2024 07:01 ET (11:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track